Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89330 | 0.88 | LMNA (0.55) | MAOBMEN1KMT2ASMN1; SMN2NR4A2 | |
| SCHEMBL8896523 | 0.87 | MEN1 (0.50) | MAOBMEN1KMT2AALDH1A1HTT | |
| SCHEMBL2450743 | 0.86 | MAOB (0.77) | MAOBMEN1KMT2AALDH1A1HTT | |
| SCHEMBL13599949 | 0.86 | MEN1 (0.49) | MAOBMEN1KMT2ANR4A2 | |
| SCHEMBL7419857 | 0.84 | GRM5 (0.51) | MAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL200874 | 0.83 | HSD11B1 (0.46) | MAOBMEN1KMT2A | |
| SCHEMBL3718587 | 0.83 | LTB4R (0.52) | MEN1KMT2ANR4A2 | |
| SCHEMBL27797837 | 0.82 | MEN1 (0.45) | MAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL23525921 | 0.82 | MAOB (0.64) | MAOBMEN1KMT2AALDH1A1HTT | |
| SCHEMBL1592632 | 0.81 | MEN1 (0.47) | MAOBMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449599-B2 | Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK + CO INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070254958-A1 | Phenyl Carboxamide Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254958-A1 | Phenyl Carboxamide Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, APP | MAOB 319/4885MEN1 3310/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.